“Frankfurt, 13th Reuters” -British pharmaceutical giant AstraZeneca has announced that it has agreed to acquire US pharmaceutical company Alexion Pharmaceutical for $ 39 billion, although it is growing rapidly. Expand business from the therapeutic drug field to the field of intractable diseases and immunology.
This acquisition is the largest ever for AstraZeneca. Pascal Soliot, CEO of the company, said in a statement, “(This acquisition) will enable us to address diseases, doctors and patients in new areas that we have not been able to address before. Our development in the field of immunity. It will be a huge opportunity to accelerate. “
The acquisition will be for one Alexion share for $ 60 in cash and a share exchange (UK-listed stock or American Depositary Receipt) for about $ 115. The total amount will be $ 175 per share, which is higher than Alexion’s closing price of $ 121 on the 11th.
AstraZeneca was initially at the forefront of the world in the race to develop a vaccine against the new coronavirus, but has since fallen behind the Pfizer / Biontech coalition and Moderna.
Mr. Soliot said he expects to apply for approval from US authorities in the next six weeks, given the favorable results of the clinical trial, regarding the status of vaccine development.
Our Code of Conduct: Thomson Reuters “Principle of Trust”